| abstract |
The present invention relates to 3- (1- {3- [5- (1-methyl-piperidin-4-ylmethoxy) -pyrnidin-2-yl] -benzyl} -6-oxo-1,6 hydrochloride solvates -dihydro-pyridazin-3-yl) - benzonitrile and its crystalline modifications. The present invention also relates to processes for preparing these crystalline modifications as well as their use in the treatment and / or prophylaxis of physiological and / or pathophysiological conditions, which are caused, mediated and / or propagated by inhibition, regulation and / or modulation of kinase transduction signals, in particular by the inhibition of tyrosine kinases, for example pathophysiological conditions such as cancer. |